Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry

Introduction To describe clinical characteristics of patients in Japan with coronavirus disease 19 (COVID-19) and pre-existing rheumatic disease and examine the possible risk factors associated with severe COVID-19. Methods Adults with rheumatic disease and a COVID-19 diagnosis who were registered in the COVID-19 Global Rheumatology Alliance (C19-GRA) physician-reported registry from Japan between 15 May 2020 and 12 May 2021 were included. Multivariable logistic regression models were used to assess factors associated with severe COVID-19 progression, defined as death or requiring oxygen inhalation. Results In total, 222 patients were included in the study. Rheumatoid arthritis (48.2%), gout (14.4%), and systemic lupus erythematosus (8.1%) were the most common types of rheumatic disease, 55.1% of patients were in remission and 66.2% had comorbid disease. Most patients were hospitalised (86.9%) for COVID-19, 43.3% received oxygen, and 9.0% died. Older age (≥ 65 years), corticosteroid use, comorbid diabetes, and lung diseases are associated with higher risk for severe COVID-19 progression (odds ratio (OR) 3.52 [95% confidence interval (CI) 1.69–7.33], OR 2.68 [95% CI 1.23–5.83], OR 3.56 [95% CI 1.42–8.88], and OR 2.59 [95% CI 1.10–6.09], respectively). Conclusions This study described clinical characteristics of COVID-19 patients with rheumatic diseases in Japan. Several possible risk factors for severe COVID-19 progression were suggested. Key points• Clinical characteristics of 222 adult patients in Japan with coronavirus disease 19 (COVID-19) and pre-existing rheumatic diseases were described.• Most patients were hospitalised (86.9%) for COVID-19 in Japan, 43.3% received oxygen, and 9.0% died.• The COVID-19 characteristics of patients with rheumatic diseases did not show any obvious different pattern from those of the general population in Japan.• In this study, older age (≥ 65 years), corticosteroid use, comorbid diabetes, and lung diseases are associated with higher risk for severe COVID-19 progression..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:41

Enthalten in:

Clinical rheumatology - 41(2022), 12 vom: 16. Aug., Seite 3661-3673

Sprache:

Englisch

Beteiligte Personen:

Kihara, Mari [VerfasserIn]
Sugihara, Takahiko [VerfasserIn]
Asano, Junichi [VerfasserIn]
Sato, Midori [VerfasserIn]
Kaneko, Hiroshi [VerfasserIn]
Muraoka, Sei [VerfasserIn]
Ohshima, Shiro [VerfasserIn]
Nanki, Toshihiro [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

BKL:

44.00$jMedizin: Allgemeines

44.83$jRheumatologie$jOrthopädie

Themen:

Antirheumatic agents
Coronavirus disease 2019
Observational
Rheumatic diseases
Risk factors

Anmerkungen:

© The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s10067-022-06305-w

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2132689490

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?